Certara, 약물 후보의 원치 않는 부작용 위험을 조기에 예측하기 위한 Secondary Intelligence™ 소프트웨어 출시
First-of-its-kind software predicts likelihood of off-target safety issues that could impede clinical progress PRINCETON, NJ – 5월 4, 2021, Certara, Inc. 글로벌 바이오시뮬레이션 선두기업(Nasdaq: CERT), the global leader in biosimulation, today announced the launch of its Secondary Intelligence™ software, the first and only software that quantitatively predicts the risk of adverse effects and safety issues derived from … Continued